Diabetes Mellitus Is Not Associated With Enhanced Bleeding Risk In Patients After Percutaneous Coronary Intervention

Dual platelet inhibition (DAPT) is crucial after percutaneous coronary intervention (PCI), especially for diabetes mellitus (DM) patients. Guidelines recommend 3-12 months of DAPT post PCI (1). However, prolongation up to 30 months is discussed. Moreover, additional vascular-dose rivaroxaban has been shown to reduce mortality (2). The associated increased bleeding risk, however, is fairly neglected. Several studies showed enhanced (3, 4), while others found equal or decreased bleeding risk in DM (5-8). This has direct implications for DAPT. Therefore, we investigated bleeding in post PCI patients with DM.